• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech Holdings S.A.

Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination
June 07, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®
May 24, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
May 16, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
May 11, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock Exchange
April 19, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
April 06, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®
February 28, 2022
From Alvotech Holdings S.A.
Via Business Wire
Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan
February 23, 2022
From Alvotech Holdings S.A.
Via Business Wire
Alvotech Enters Exclusive Global Licensing Agreement with BiosanaPharma for Co-Development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)
February 02, 2022
From Alvotech Holdings S.A.
Via Business Wire
Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million
January 18, 2022
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
December 07, 2021
From Alvotech Holdings S.A.
Via Business Wire
Tickers OACB
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap